$BVS News

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19

Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review

Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate

Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est

Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)

Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Transcript: Bioventus Q1 2026 Earnings Conference Call

Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing

Is Bioventus (BVS) Stock Undervalued Right Now?

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?

Bioventus Inc. Q1 2026 Earnings Call Summary

Bioventus (BVS) Q1 2026 Earnings Transcript

Bioventus Q1 Earnings Call Highlights

Bioventus Inc. (BVS) Q1 2026 Earnings Call Transcript

Bioventus (BVS) Surpasses Q1 Earnings and Revenue Estimates